CEO Executive AssistantRegulatory submissions are among the highest-stakes deliverables in the pharmaceutical industry. An NDA, BLA, or IND filing can make or break a product’s commercial trajectory, and the FDA relationship that surrounds those submissions requires careful cultivation and precise management. It is understandable that pharma CEOs feel compelled to stay close to regulatory work. What is less understandable, and ultimately counterproductive, is when that closeness becomes hands-on involvement in tasks that a well-built regulatory affairs team should own.
Effective delegation in regulatory submissions does not mean the CEO steps back from high-stakes decisions. It means the CEO stops doing work that regulatory affairs professionals are better positioned to do, and instead reserves their energy for the moments where CEO-level leadership genuinely moves the needle.
Understanding the CEO’s True Role in Regulatory Affairs
The pharmaceutical CEO’s value in regulatory matters is not in drafting submission sections, managing eCTD formatting, or tracking FDA correspondence. It lies in three areas: strategic direction, external relationship leverage, and organizational prioritization.
When a regulatory submission requires a difficult strategic decision, such as whether to pursue accelerated approval, how to respond to a complete response letter, or whether to request a Type A meeting with the FDA, the CEO’s judgment is essential. When a funder, board member, or public stakeholder needs to hear directly from the CEO about the company’s regulatory pathway, that is a CEO function. When resource constraints threaten a submission timeline and a cross-functional tradeoff is needed, the CEO must decide.
Everything else belongs to the regulatory affairs team.
Step 1: Build a Regulatory Affairs Team With Real Authority
The most common reason pharma CEOs retain too much regulatory work is that their regulatory affairs team lacks the seniority, authority, or staffing to operate independently. A Chief Regulatory Officer or VP of Regulatory Affairs who must escalate routine decisions to the CEO is not truly leading the regulatory function.
Before delegating submission work, assess whether your regulatory affairs leader has:
- Full authority to interact with the FDA on operational and procedural matters without CEO pre-approval
- Staff sufficient to manage the current submission pipeline without using CEO bandwidth as a buffer
- A clear mandate to own the submission calendar, track deadlines, and report on regulatory milestones
- The organizational standing to coordinate cross-functionally with clinical, CMC, and medical affairs without CEO facilitation
If any of these elements are missing, address them before expecting delegation to work. Delegation fails when the recipient lacks the authority to act, not just the willingness.
Step 2: Delegate FDA Interaction With Defined Escalation Rules
FDA meetings, correspondence, and agency relationships are an area where many pharma CEOs insist on personal involvement. Some of that involvement is warranted. Most is not.
A practical framework divides FDA interactions into three tiers:
Tier 1 - Delegated fully to regulatory affairs. This includes routine FDA correspondence, information request responses, IND annual reports, meeting minutes review, and Type B and C meeting logistics. The regulatory affairs team owns these interactions end-to-end. The CEO receives a summary briefing but is not involved in execution.
Tier 2 - Regulatory affairs leads, CEO informed in advance. This includes Type A meetings for important pipeline programs, major amendment submissions, and formal responses to FDA deficiency letters. The regulatory affairs team prepares and leads these interactions, but the CEO is briefed on strategy and positioning before engagement.
Tier 3 - CEO participates directly. This includes FDA Advisory Committee meetings, meetings with the FDA Commissioner or senior leadership where organizational credibility is at stake, and situations involving significant public health or legal exposure. The CEO participates alongside regulatory affairs leadership, not instead of them.
Documenting this framework and sharing it with the regulatory affairs team removes ambiguity and stops the pattern where every FDA interaction triggers a CEO availability check.
Step 3: Establish a Submission Management System the CEO Reviews, Not Runs
Submission project management is one of the most process-intensive aspects of regulatory affairs. An NDA or BLA submission requires coordinating hundreds of documents, dozens of contributors, and a compressed timeline where delays cascade quickly. This work should be owned by a Regulatory Project Manager or equivalent role, not absorbed by the CEO.
The CEO’s interface with submission management should be through a clean, concise reporting structure:
- Weekly: A one-page submission status update covering milestone progress, upcoming deadlines, open issues, and any decisions requiring CEO input. This should take no more than ten minutes to review.
- Monthly: A thirty-minute regulatory affairs review meeting where the CRO or VP walks through pipeline status, emerging FDA guidance, and strategic regulatory decisions on the horizon.
- As needed: Immediate escalation for any FDA communication that significantly changes the regulatory pathway, any submission delay that affects investor or board commitments, or any safety signal with regulatory implications.
This structure keeps the CEO fully informed without requiring participation in the daily coordination that consumes regulatory project managers.
Step 4: Delegate Submission Writing and Quality Review
Submission document preparation, including clinical summaries, CMC sections, nonclinical overviews, and the integrated summary of safety and efficacy, should be written and reviewed by subject matter experts and regulatory writers, not reviewed by the CEO.
The CEO is not the right person to evaluate whether a clinical summary accurately represents the statistical analysis or whether a CMC section complies with current FDA guidance. Attempting to review these documents at a technical level creates bottlenecks, introduces errors from outside-expertise edits, and gives the regulatory team the false impression that the CEO is a reviewer they need to satisfy rather than a leader they are accountable to.
The CEO should review one thing at the submission level: the executive summary or cover letter that represents the organization’s strategic narrative for the filing. This document communicates why this drug matters, why the data support approval, and what the company is committing to in terms of post-market obligations. That is a CEO-level document. Everything behind it is a regulatory affairs document.
Step 5: Manage CRO and Regulatory Consultant Relationships Through Your CRO
Many pharma companies, particularly those in mid-size or clinical-stage settings, rely on contract research organizations and regulatory consultants to supplement internal submission capabilities. These relationships often involve significant financial commitments and strategic dependencies, which pulls CEO attention.
The right model is for the Chief Regulatory Officer or VP of Regulatory Affairs to own all CRO and regulatory consultant relationships operationally, with the CEO involved in contract approval above a defined dollar threshold and in strategic vendor decisions that affect multiple programs. The regulatory affairs leader manages scope, performance, and day-to-day coordination.
When CEOs remain directly involved in vendor relationships below this threshold, they signal to the regulatory affairs team that they do not trust the team to manage those relationships, which undermines accountability and creates a culture of escalation.
Step 6: Align Board and Investor Communication With Regulatory Milestones
One of the legitimate CEO responsibilities in regulatory affairs is translating regulatory milestones into language that boards, investors, and the public can understand and act on. PDUFA dates, complete response letters, and FDA advisory committee votes all carry significant organizational implications that the CEO must communicate.
However, the preparation behind those communications should be a collaborative product. The regulatory affairs team provides the technical facts and regulatory context. The CFO and investor relations team provide the market context. The CEO synthesizes these inputs into the external message. The CEO should not be researching FDA precedent or drafting regulatory background sections of investor updates.
According to McKinsey & Company, pharmaceutical executives who focus on strategic decisions and delegate operational complexity to specialized teams navigate regulatory pathways more efficiently and with fewer organizational bottlenecks.
For additional frameworks on how pharma CEOs build delegation structures across their organizations, see our guide on pharma delegation strategies, which covers the clinical trial management dimension of the regulatory relationship. Our resource on pharma regulatory delegation provides a comprehensive matrix for assigning regulatory responsibilities across the leadership team.
Common Delegation Pitfalls in Regulatory Affairs
Reviewing submissions at a detail level. CEO review of technical submission content creates delays, undermines the regulatory team’s authority, and rarely improves submission quality. Reserve CEO review for strategic narrative and organizational commitments.
Being the single point of contact with FDA. If the FDA’s primary relationship is with the CEO rather than the regulatory affairs team, you are building organizational fragility. Work to transfer primary FDA contact to the CRO or VP of Regulatory Affairs while maintaining CEO availability for senior FDA engagement.
Conflating regulatory risk with CEO task ownership. High stakes do not mean the CEO should do the work. High stakes mean the CEO should ensure the right people with the right authority are doing the work with the right support.
Conclusion
Pharma CEOs who delegate regulatory submissions effectively spend their time making the strategic decisions that shape the regulatory pathway, communicating with boards and investors about regulatory milestones, and engaging with FDA leadership at the level where CEO credibility matters. They stay informed through clean reporting structures and defined escalation rules without getting pulled into submission project management or technical document review.
Building this model requires investment in regulatory affairs leadership and a willingness to release operational control. The return is a faster, more consistent regulatory process and a CEO who has the bandwidth to lead the entire organization, not just its most complex filing.
Related Reading
For further context, explore Delegation Tips for AI Startup CEOs and Delegation Tips for Automotive CEO: Digital Teams.